Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia

BACKGROUND: Eltrombopag is a thrombopoietin receptor agonist with excellent treatment outcomes in immune thrombocytopenia (ITP). Here, we analyzed the dose of eltrombopag required to achieve and maintain safe platelet counts in Korean ITP patients. METHODS: Adult refractory ITP patients (<30,000...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Res
Main Authors: Kim, Yeo-Kyeoung, Lee, Seung-Sin, Jeong, Sung-Hoon, Ahn, Jae-Sook, Yang, Deok-Hwan, Lee, Je-Jung, Kim, Hyeoung-Joon
Format: Artigo
Jezik:Inglês
Izdano: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2015
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4377333/
https://ncbi.nlm.nih.gov/pubmed/25830126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5045/br.2015.50.1.19
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki